Jesang Lee

Mr. Jesang Lee

Chemistry, Seoul National University, Seoul, Republic of Korea
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2021 in Nature
Verified
Journal Article
Closed access
PDF file
SOSungwhan F. Oh
Sungwhan F. Oh
TPT. Praveena
T. Praveena
HSHeebum Song
Heebum Song
JYJi-Sun Yoo
Ji-Sun Yoo
DJDa-Jung Jung
Da-Jung Jung
DKDennis L. Kasper
Dennis L. Kasper

27 November 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
JLJesang Lee
Jesang Lee
Seung Bum ParkSeung Bum Park
Seung Bum Park
Recently, small-molecule covalent inhibitors have been accepted as a practical tool for targeting previously “undruggable” proteins. The high target selectivity of modern covalent inhibitors is now alleviating toxicity concerns regarding the covalent modifications of proteins. However, despite the tremendous clinical success of current covalent inhibitors, there are still unmet medical needs that covalent inhibitors have not yet addressed. This review categorized representative covalent inhibitors based on their mechanism of covalent inhibition: conventional covalent inhibitors, targeted covalent inhibitors (TCIs), and expanded TCIs. By reviewing both Food and Drug Administration (FDA)-approved drugs and drug candidates from recent literature, we provide insight into the future direction of covalent inhibitor development.

1 April 2025 in Communications Chemistry
Verified
Journal Article
Open access
PDF file
JLJesang Lee
Jesang Lee
SSSumin Son
Sumin Son
MLMinha Lee
Minha Lee
Seung Bum ParkSeung Bum Park
Seung Bum Park
α-Galactosylceramide (α-GalCer) is a prototypical antigen recognized by natural killer T (NKT) cells, a subset of T cells crucial for immune regulation. Despite its significance, the complex structure-activity relationship of α-GalCer and its analogs remains poorly understood, particularly in defining the structural determinants of NKT cell responses. In this study, we designed and synthesized potential immunomodulatory ligands targeting NKT cells, inspired by glycolipids derived from the gut symbiont Bacteroides fragilis. A series of α-GalCer analogs with terminal iso-branched sphinganine backbones was developed through rational modification of the acyl chain. Our results identified the C3′ hydroxyl group as a structural element that impairs glycolipid presentation by CD1d, as evidenced by reduced IL-2 secretion and weak competition with a potent CD1d ligand. Notably, among C3′-deoxy α-GalCer analogs, those containing an α-chloroacetamide group exhibited robust NKT cell activation with Th2 selectivity. Computational docking and mass spectrometry analyses further confirmed the substantial interaction of α-chloroacetamide analogs to CD1d. These findings underscore the potential of leveraging microbiota-derived glycolipid structures to selectively modulate NKT cell functions for therapeutic purposes.

11 August 2026 in Angewandte Chemie
Verified
Journal Article
Open access
JLJesang Lee
Jesang Lee
SSSumin Son
Sumin Son
JYJeong Yeon Yoo
Jeong Yeon Yoo
JLJi Hyae Lee
Ji Hyae Lee
MCMeehyun Chun
Meehyun Chun
Seung Bum ParkSeung Bum Park
Seung Bum Park
Peptidomimetics have matured from motif‑based inhibitors into a structural engineering discipline that systematically translates peptide recognition surfaces into drug‑like scaffolds. Driven by the urgent clinical demand to overcome the inherent pharmacological liabilities of biomolecules, the field is undergoing a decisive Peptide‐to‐Small Molecule paradigm shift—functionally converting peptide‐derived recognition motifs into orally bioavailable synthetic therapeutics. This Perspective highlights how foundational geometric design principles—linear repetition, convergent fusion, and cyclization—define next‑generation architectures capable of targeting complex protein–protein interactions (PPIs). Repeating‑unit oligomers exemplify linear projection strategies, heterocycle‑centered scaffolds embody the convergent fusion of recognition motifs, and macrocyclic frameworks pre‐organize bioactive conformations while enabling access to non‑canonical topologies. Beyond simple mimicry, these architectures increasingly embrace dynamic responsiveness, aggregation remodeling, and universal multi‑structure platforms. We argue that the convergence of geometric logic with automated synthesis and AI‑driven design will transform peptidomimetics into a primary modality for decoding and therapeutically engaging the human interactome, including historically “undruggable” PPIs.

10 August 2026 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
JLJesang Lee
Jesang Lee
SSSumin Son
Sumin Son
JYJeong Yeon Yoo
Jeong Yeon Yoo
JLJi Hyae Lee
Ji Hyae Lee
MCMeehyun Chun
Meehyun Chun
Seung Bum ParkSeung Bum Park
Seung Bum Park
Peptidomimetics have matured from motif‑based inhibitors into a structural engineering discipline that systematically translates peptide recognition surfaces into drug‑like scaffolds. Driven by the urgent clinical demand to overcome the inherent pharmacological liabilities of biomolecules, the field is undergoing a decisive Peptide‐to‐Small Molecule paradigm shift—functionally converting peptide‐derived recognition motifs into orally bioavailable synthetic therapeutics. This Perspective highlights how foundational geometric design principles—linear repetition, convergent fusion, and cyclization—define next‑generation architectures capable of targeting complex protein–protein interactions (PPIs). Repeating‑unit oligomers exemplify linear projection strategies, heterocycle‑centered scaffolds embody the convergent fusion of recognition motifs, and macrocyclic frameworks pre‐organize bioactive conformations while enabling access to non‑canonical topologies. Beyond simple mimicry, these architectures increasingly embrace dynamic responsiveness, aggregation remodeling, and universal multi‑structure platforms. We argue that the convergence of geometric logic with automated synthesis and AI‑driven design will transform peptidomimetics into a primary modality for decoding and therapeutically engaging the human interactome, including historically “undruggable” PPIs.